Semaglutide (Wegovy) for Weight Loss
Semaglutide (Wegovy) for Weight Loss
July 12, 2021 (Issue: 1628)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and...more
- Semaglutide (Ozempic) – another injectable GLP-1 receptor agonist for type 2 diabetes. Med Lett Drugs Ther 2018; 60:19.
- Oral semaglutide (Rybelsus) for type 2 diabetes. Med Lett Drugs Ther 2019; 61:166.
- Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015; 57:89.
- Diet, drugs, devices, and surgery for weight management. Med Lett Drugs Ther 2018; 60:91.
- SE Kanoski et al. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 2016; 310:R885.
- JPH Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
- TA Wadden et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021; 325:1403.
- D Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021; 325:1414.
- M Davies et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397:971.
- PM O’Neil et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392:637.
- T Wang et al. Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system. Diabetes Care 2019; 42:e21.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Semaglutide (Wegovy) for Weight Loss
Article code: 1628b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
